The critical role of histology in an era of genomics and proteomics: A commentary and reflection

Advances in Anatomic Pathology

Volumn 14, Issue 6, 2007, Pages 375-400

  Nathwani, Bharat N ^a   Sasu, Sebastian J ^b   Ahsanuddin, Arshad N ^d   Hernandez, Antonio M ^e   Drachenberg, Milton R ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b SAINT JOHN'S HEALTH CENTER   (United States)

^c LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Center for Advanced Diagnostics   (United States)

Author keywords

Histology; Lymphoma; Morphology

Indexed keywords

B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CELL DIFFERENTIATION; CLINICAL FEATURE; CYTOGENETICS; CYTOLOGY; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; GENOMICS; HISTOLOGY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; MORPHOLOGY; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEOMICS; REVIEW; T CELL LYMPHOMA; WORLD HEALTH ORGANIZATION;

FLOW CYTOMETRY; GENOMICS; HISTOLOGICAL TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; PROTEOMICS;

EID: 37349007596     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e318159479d     Document Type: Review

References (201)

1. Jaffe ES, Harris NL, Stein H, et al. ed. World Health Organization Classification of Tumours. Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyons: IARC Press; 2001:351.
2. Nathwani BN, Sasu SJ, Ahsanuddin AN, et al. The art of histological diagnosis. In: Magrath IT, ed. The Lymphoid Neoplasms, 3rd ed. London: Hodder & Stoughton, Ltd; 2008. Accepted for publication.
3. Nathwani BN, Hernandez AM, Drachenberg MR. Diagnostic significance of morphologic patterns of lymphoid proliferations in lymph nodes. In: Knowles DM, ed. Neoplastic Hematopathology, 2nd ed. Philadelphia: Lippincott, Williams & Wilkins; 2001: 507-536.
4. Bagg A. Clinical applications of molecular genetic testing in hematologic malignancies: advantages and limitations. Hum Pathol. 2003;34:352-358.
5. Bagg A. Role of molecular studies in the classification of lymphoma. Expert Rev Mol Diagn. 2004;4:83-97.
6. Kuppers R, Schmitz R, Distler V, et al. Pathogenesis of Hodgkin's lymphoma. Eur J Haematol Suppl. 2005;26-33.
7. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci USA. 1994;91:10962-10966.
8. Bagg A. Molecular diagnosis in lymphoma. Curr Hematol Rep. 2005;4:313-323.
9. Alizadeh A, Eisen M, Davis RE, et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol. 1999;64:71-78.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
11. Bichsel VE, Liotta LA, Petricoin EF III. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J. 2001;7:69-78.
12. Chan WC. Gene expression profiling in lymphoma diagnosis and research. Croat Med J. 2005;46:349-359.
13. Conrads TP, Hood BL, Petricoin EF III, et al. Cancer proteomics: many technologies, one goal. Expert Rev Proteomics. 2005;2:693-703.
14. Espina V, Woodhouse EC, Wulfkuhle J, et al. Protein microarray detection strategies: focus on direct detection technologies. J Immunol Methods. 2004;290:121-133.
15. Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med. 2003;348:1777-1785.
16. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163-208.
17. Isaacson PG, Du MQ. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol. 2005;205:255-274.
18. Kees UR. Gene expression signatures in lymphoid tumours. Immunol Cell Biol. 2004;82:154-160.
19. Chan WC, Fu K. Molecular diagnostics on lymphoid malignancies. Arch Pathol Lab Med. 2004;128:1379-1384.
20. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102:3871-3879.
21. Monti S, Savage KJ, Kutok JL, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851-1861.
22. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
23. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851-862.
24. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell. 2003;3:185-197.
25. Rubio-Moscardo F, Climent J, Siebert R, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood. 2005;105:4445-4454.
26. Thieblemont C, Nasser V, Felman P, et al. Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. Blood. 2004;103:2727-2737.
27. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. Hum Pathol. 2005;36:494-504.
28. Dybkaer K, Iqbal J, Zhou G, et al. Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma. Clin Lymphoma. 2004;5:19-28.
29. Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy. Biosci Rep. 2005;25:107-125.
30. Carr KM, Rosenblatt K, Petricoin EF, et al. Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy. Hum Genomics. 2004;1:134-140.
31. Cho-Vega JH, Troncoso P, Do KA, et al. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples. Mod Pathol. 2005;18:577-584.
32. Espina V, Geho D, Mehta AI, et al. Pathology of the future: molecular profiling for targeted therapy. Cancer Invest. 2005;23:36-46.
33. Geho DH, Lahar N, Ferrari M, et al. Opportunities for nanotechnology-based innovation in tissue proteomics. Biomed Microdevices. 2004;6:231-239.
34. Tangrea MA, Chuaqui RF, Gillespie JW, et al. Expression microdissection: operator-independent retrieval of cells for molecular profiling. Diagn Mol Pathol. 2004;13:207-212.
35. Bensmail H, Aruna B, Semmes OJ, et al. Functional clustering algorithm for high-dimensional proteomics data. J Biomed Biotechnol. 2005;2005:80-86.
36. Bensmail H, Golek J, Moody MM, et al. A novel approach for clustering proteomics data using Bayesian fast Fourier transform. Bioinformatics. 2005;21:2210-2224.
37. Jackson H. Classification and prognosis of Hodgkin's disease and allied disorders. Surg Gynecol Obstet. 1937;64:465-467.
38. Jackson HJ, Parker FJ. Hodgkin's Disease and Allied Disorders. New York: Oxford University Press; 1947:34.
39. Lukes RJ. Relationship of histologic features to clinical stages in Hodgkin's disease. Am J Roentgenol Radium Ther Nucl Med. 1963;90:944-955.
40. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res. 1966;26:1063-1083.
41. Sternberg C. Ueber leukosarcomatose. Wien Klin Wchnschr. 1908; 21:475-480.
42. Cooke JV. Mediastinal tumor in acute leukemia. A clinical and roentgenologic study. Am J Dis Child. 1932;44:1153-1177.
43. Robb-Smith AH. Reticulosis and reticulosarcoma: a histological classification. J Pathol Bacteriol. 1938;47:457-481.
44. Gall EA, Mallory TB. Malignant lymphoma. A clinico-pathologic survey of 618 cases. Am J Pathol. 1942;18:381-429.
45. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg. 1958;46:218.
46. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy: a prelymphomatous state of immunoblastic sarcoma. Recent Results Cancer Res. 1978;64:241-246.
47. Lukes RJ, Tindle BH. Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease. N Engl J Med. 1975;292:1-8.
48. Frizzera G, Moran EM, Rappaport H. Angio-immunoblastic lymphadenopathy with dysproteinaemia. Lancet. 1974;1:1070-1073.
49. Nathwani BN, Rappaport H, Moran EM, et al. Malignant lymphoma arising in angioimmunoblastic lymphadenopathy. Cancer. 1978;41:578-606.
50. Lennert K, Mohri N, Stein H, et al. The histopathology of malignant lymphoma. Br J Haematol. 1975;31(suppl):193-203.
51. Braylan RC, Jaffe ES, Berard CW. Malignant lymphomas. Current classification and new observations. In: Sommers SC, ed. Pathology Annual. New York: Appleton-Centruy-Crofts; 1975: 213-270.
52. Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;52:1410-1416.
53. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
54. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society; 2006:52.
55. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood. 1997;89:3909-3918.
56. Medeiros LJ, Carr J. Overview of the role of molecular methods in the diagnosis of malignant lymphomas. Arch Pathol Lab Med. 1999;123:1189-1207.
57. Zha H, Raffeld M, Charboneau L, et al. Similarities of prosurvival signals in bcl-2-positive and bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest. 2004;84:235-244.
58. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol. 1999;36:115-127.
59. Nathwani BN, Burke JS, Winberg CD. Architectural features of normal, neoplastic, and non-neoplastic lymph nodes: A practical diagnostic approach. In: Murphy FG, Mihm MC Jr, eds. Lymphoproliferative Disorders of the Skin. Boston: Butterworths; 1983.
60. Nathwani BN. Classifying non-Hodgkin's lymphomas. In: Berard CW, Dorfman RF, Kaufman N, eds. Malignant Lymphoma. Baltimore: Williams & Wilkins; 1987:18-80.
61. Nathwani BN. Significance of morphologic patterns in lymph node proliferations. In: Knowles DM, ed. Neoplastic Hematopathology. 1st ed. Baltimore: Williams & Willkins; 1992:407-425.
62. de Jong D, Weller E, Rosenwald A, et al. Validation and standardrization of immunohistochemical prognostic markers in diffuse large B-cell lymphoma (DLBCL). XIII Meeting of the European Association for Haematopathology. Vienna, Austria. 2006. Abstract lo-24.
63. Hanson CA, Kurtin PJ, Hodnefield JM, et al. Flow cytometric analysis of peripheral blood and bone marrow in the diagnosis of malignant lymphoma. XIII Meeting of the European Association for Haematopathology. Vienna, Austria. 2006. Abstract lp-56.
64. Ho AK, Hill S, Preobrazhensky SN, et al. Cases with typical mantle cell lymphoma immunophenotypes by flow cytometry often include chronic lymphocytic leukemia. 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, California. 2007. Abstract 1117.
65. Iancu D, Hao S, Lin P, et al. Follicular lymphoma in staging bone marrow specimens: correlation of histologic findings with the results of flow cytometry immunophenotypic analysis. Arch Pathol Lab Med. 2007;131:282-287.
66. Gupta A, Lin P, Gheorghe G, et al. Absence of expression of CD34 and TdT is more common in precursor T-lymphoblastic leukemia than in precursor B-lymphoblastic leukemia. 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, California. 2007. Abstract 1108.
67. Aster JC, Kobayashi Y, Shiota M, et al. Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am J Pathol. 1992;141:291-299.
68. Hyjek E, Chadburn A, Liu YF, et al. Bcl-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. Blood. 2001;97:270-276.
69. + phenotype. Am J Surg Pathol. 2001;25:395-400.
70. Pruneri G, Valentini S, Bertolini F, et al. SP4, a novel anti-cyclin d1 rabbit monoclonal antibody, is a highly sensitive probe for identifying mantle cell lymphomas bearing the t(11;14)(q13;q32) translocation. Appl Immunohistochem Mol Morphol. 2005;13:318-322.
71. Remstein ED, Kurtin PJ, James CD, et al. Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways. Am J Pathol. 2002;161:63-71.
72. Takeshita M, Iwashita A, Kurihara K, et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol. 2000;24:1641-1649.
73. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000;156:1183-1188.
74. Mo JQ, Dimashkieh H, Mallery SR, et al. MALT lymphoma in children: case report and review of the literature. Pediatr Dev Pathol. 2004;7:407-413.
75. Paltiel O, Zelenetz A, Sverdlin I, et al. Translocation t(14;18) in healthy individuals: preliminary study of its association with family history and agricultural exposure. Ann Oncol. 2000;11(suppl 1):75-80.
76. De Wolf-Peeters C. Normal histology and immunoarchitecture of the lymphohematopoietic system. In: Knowles DM, ed. Neoplastic Hematopathology. Philadelphia: Lippincott, Williams & Wilkins; 2000:271-306.
77. Murray PG, Janmohamed RM, Crocker J. CD23 expression in non-Hodgkin lymphoma: immunohistochemical demonstration using the antibody BU38 on paraffin sections. J Pathol. 1991;165:125-128.
78. Liu Z, Dong HY, Gorczyca W, et al. CD5-mantle cell lymphoma. Am J Clin Pathol. 2002;118:216-224.
79. Dogan A, Bagdi E, Munson P, et al. CD10 and bcl-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000;24:846-852.
80. + extranodal marginal zone B-cell (MALT) lymphoma. A low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol. 1996;105:31-37.
81. Tiemann M, Schrader C, Klapper W, et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL network. Br J Haematol. 2005;131:29-38.
82. Wohlschlaeger C, Lange K, Merz H, et al. Aberrant immunophenotypes of mantle cell lymphomas. Leuk Lymphoma. 2003;44:269-273.
83. Specht K, Kremer M, Muller U, et al. Identification of cyclin d1 mRNA overexpression in B-cell neoplasias by real-time reverse transcription-PCR of microdissected paraffin sections. Clin Cancer Res. 2002;8:2902-2911.
84. Schroers R, Griesinger F, Trumper L, et al. Combined analysis of zap-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia. 2005;19:750-758.
85. Willenbrock K, Roers A, Seidl C, et al. Analysis of T-cell subpopulations in T-cell non-Hodgkin's lymphoma of angioimmunoblastic lymphadenopathy with dysproteinemia type by single target gene amplification of T cell receptor-beta gene rearrangements. Am J Pathol. 2001;158:1851-1857.
86. Willenbrock K, Renne C, Gaulard P, et al. In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. Virchows Arch. 2005;446:15-20.
87. Pinkus GS, Pinkus JL, Langhoff E, et al. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease. Evidence for a dendritic or B cell derivation? Am J Pathol. 1997;150:543-562.
88. Brauninger A, Wacker HH, Rajewsky K, et al. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res. 2003;63:1644-1651.
89. Tzankov A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol. 2003;16:1141-1147.
90. Cook JR, Galle D, Nowak N, et al. Array-based comparative genomic hybridization of occular adnexal malt lymphoma. 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, California. 2007. Abstract 1089.
91. Remstein ED, Law ME, Dewald GW, et al. CPG oligonucleotides induce growth of MALT lymphoma cells in vitro and reveal novel cytogenetic abnormalities [abtract 1180]. 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, California. 2007.
92. Streubel B, Bilban M, Raderer M, et al. MALT lymphoma: novel translocations and three distinct gene expression profiles. 96th Annual Meeting of the United States and Canadian Academy of Pathology. San Diego, California. 2007. Abstract 1196.
93. Limpens J, de Jong D, van Krieken JH, et al. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene. 1991;6:2271-2276.
94. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood. 1995;85:2528-2536.
95. Antonucci F, Chilosi M, Santacatterina M, et al. Proteomics and immunomapping of reactive lymph-node and lymphoma. Electrophoresis. 2002;23:356-362.
96. Leak LV, Liotta LA, Krutzsch H, et al. Proteomic analysis of lymph. Proteomics. 2004;4:753-765.
97. Schmechel SC, LeVasseur RJ, Yang KH, et al. Identification of genes whose expression patterns differ in benign lymphoid tissue and follicular, mantle cell, and small lymphocytic lymphoma. Leukemia. 2004;18:841-855.
98. Zukerberg LR, Medeiros LJ, Ferry JA, et al. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features. Am J Clin Pathol. 1993;100:373-385.
99. Harris NL, Ferry JA. Follicular lymphoma. In: Knowles DM, ed. Neoplastic Hematopathology. Philadelphia: Lippincott, Williams & Wilkins; 2000:823-854.
100. Swerdlow SH. Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. Am J Clin Pathol. 2004;122(suppl):S98-S109.
101. Lai R, Arber DA, Chang KL, et al. Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol. 1998;11:864-869.
102. Barcus ME, Karageorge LS, Veloso YL, et al. CD10 expression in follicular lymphoma versus reactive follicular hyperplasia: evaluation in paraffin-embedded tissue. Appl Immunohistochem Mol Morphol. 2000;8:263-266.
103. Chan JKC. Tumors of the lymphoreticular system. In: Fletcher CDM, ed. Diagnostic Histopathology of Tumors. New York: Churchill-Livingstone; 2000:1099-1316.
104. Skinnider BF, Horsman DE, Dupuis B, et al. Bcl-6 and bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol. 1999;30:803-808.
105. Ree HJ, Kadin ME, Kikuchi M, et al. Bcl-6 expression in reactive follicular hyperplasia, follicular lymphoma, and angioimmunoblastic T-cell lymphoma with hyperplastic germinal centers: heterogeneity of intrafollicular T-cells and their altered distribution in the pathogenesis of angioimmunoblastic T-cell lymphoma. Hum Pathol. 1999;30:403-411.
106. Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood. 2005;106:1501-1502.
107. Dong HY, Gorczyca W, Liu Z, et al. B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol. 2003;119:218-230.
108. Fuscoe JC, Setzer RW, Collard DD, et al. Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogens. Carcinogenesis. 1996;17:1013-1020.
109. Horsman DE, Okamoto I, Ludkovski O, et al. Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. Br J Haematol. 2003;120:424-433.
110. Jardin F, Gaulard P, Buchonnet G, et al. Follicular lymphoma without t(14;18) and with bcl-6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics. Leukemia. 2002;16:2309-2317.
111. + follicle center lymphoma. Immunophenotyping detects a unique subset of ''floral'' follicular lymphoma. Am J Clin Pathol. 2000;114:912-921.
112. Luo JH, Matsushima AY, Chen R, et al. Detection of CD5 antigen on B cell lymphomas in fixed, paraffin embedded tissues using signal amplification by catalyzed reporter deposition. Eur J Histochem. 1998;42:31-39.
113. Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Am J Clin Pathol. 2003;120:760-766.
114. Kumar S, Green GA, Teruya-Feldstein J, et al. Use of CD23 (BU38) on paraffin sections in the diagnosis of small lymphocytic lymphoma and mantle cell lymphoma. Mod Pathol. 1996;9:925-929.
115. Torlakovic E, Nielsen S, Vyberg M. Antibody selection in immunohistochemical detection of cyclin d1 in mantle cell lymphoma. Am J Clin Pathol. 2005;124:782-789.
116. Cheuk W, Wong KO, Wong CS, et al. Consistent immunostaining for cyclin d1 can be achieved on a routine basis using a newly available rabbit monoclonal antibody. Am J Surg Pathol. 2004;28:801-807.
117. Wenzel C, Dieckmann K, Fiebiger W, et al. CD5 expression in a lymphoma of the mucosa-associated lymphoid tissue (MALT)-type as a marker for early dissemination and aggressive clinical behaviour. Leuk Lymphoma. 2001;42:823-829.
118. Nakamura S, Seto M, Banno S, et al. Immunohistochemical analysis of cyclin d1 protein in hematopoietic neoplasms with special reference to mantle cell lymphoma. Jpn J Cancer Res. 1994;85:1270-1279.
119. de Boer CJ, van Krieken JH, Schuuring E, et al. Bcl-1/cyclin d1 in malignant lymphoma. Ann Oncol. 1997;8(suppl 2):109-117.
120. Hui P, Howe JG, Crouch J, et al. Real-time quantitative RT-PCR of cyclin d1 mRNA in mantle cell lymphoma: comparison with fish and immunohistochemistry. Leuk Lymphoma. 2003;44:1385-1394.
121. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin d1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin d1-positive MCL and cyclin d1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253-2261.
122. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin d1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood. 2005;106:4315-4321.
123. Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol. 2005;23:6415-6420.
124. Isaacson PG, Wotherspoon AC, Diss T, et al. Follicular colonization in B-cell lymphoma of mucosa-associated lymphoid tissue. Am J Surg Pathol. 1991;15:819-828.
125. Hernandez AM, Nathwani BN, Nguyen D, et al. Nodal benign and malignant monocytoid B cells with and without follicular lymphomas: a comparative study of follicular colonization, light chain restriction, bcl-2, and t(14;18) in 39 cases. Hum Pathol. 1995;26:625-632.
126. Nathwani BN, Mohrmann RL, Brynes RK, et al. Monocytoid B-cell lymphomas: an assessment of diagnostic criteria and a perspective on histogenesis. Hum Pathol. 1992;23:1061-1071.
127. Arends JE, Bot FJ, Gisbertz IA, et al. Expression of CD10, CD75 and CD43 in MALT lymphoma and their usefulness in discriminating MALT lymphoma from follicular lymphoma and chronic gastritis. Histopathology. 1999;35:209-215.
128. + follicular lymphomas. Am J Clin Pathol. 1999;111:488-494.
129. Dogan A, Isaacson PG. Splenic marginal zone lymphoma. Semin Diagn Pathol. 2003;20:121-127.
130. Attygalle AD, Liu H, Shirali S, et al. Atypical marginal zone hyperplasia of mucosa-associated lymphoid tissue: a reactive condition of childhood showing immunoglobulin lambda light-chain restriction. Blood. 2004;104:3343-3348.
131. Campo E, Miquel R, Krenacs L, et al. Primary nodal marginal zone lymphomas of splenic and MALT type. Am J Surg Pathol. 1999;23:59-68.
132. Taddesse-Heath L, Pittaluga S, Sorbara L, et al. Marginal zone B-cell lymphoma in children and young adults. Am J Surg Pathol. 2003;27:522-531.
133. Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol. 2005;18:57-68.
134. Streubel B, Vinatzer U, Lamprecht A, et al. t(3;14)(p14.1;q32) involving IgH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma. Leukemia. 2005;19:652-658.
135. Streubel B, Lamprecht A, Dierlamm J, et al. t(14;18)(q32;q21) involving IgH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood. 2003;101:2335-2339.
136. Ye H, Liu H, Attygalle A, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood. 2003;102:1012-1018.
137. Willis TG, Jadayel DM, Du MQ, et al. Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell. 1999;96:35-45.
138. Matrai Z. CD38 as a prognostic marker in CLL. Hematology. 2005;10:39-46.
139. Mainou-Fowler T, Dignum HM, Proctor SJ, et al. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma. 2004;45:455-462.
140. Wiestner A, Rosenwald A, Barry TS, et al. Zap-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101:4944-4951.
141. Rassenti LZ, Huynh L, Toy TL, et al. Zap-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
142. Orchard JA, Ibbotson RE, Davis Z, et al. Zap-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105-111.
143. Cartron G, Linassier C, Bremond JL, et al. CD5 negative B-cell chronic lymphocytic leukemia: clinical and biological features of 42 cases. Leuk Lymphoma. 1998;31:209-216.
144. Zukerberg LR, Yang WI, Arnold A, et al. Cyclin d1 expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol. 1995;103:756-760.
145. Yang WI, Zukerberg LR, Motokura T, et al. Cyclin d1 (bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol. 1994;145:86-96.
146. Letestu R, Rawstron A, Ghia P, et al. Evaluation of zap-70 expression by flow cytometry in chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry B Clin Cytom. 2006;70:309-314.
147. Dohner H, Stilgenbauer S, Dohner K, et al. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999;77:266-281.
148. Sindelarova L, Michalova K, Zemanova Z, et al. Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2005;160:27-34.
149. Acar H, Connor MJ. Detection of trisomy 12 and centromeric alterations in CLL by interphase- and metaphase-FISH. Cancer Genet Cytogenet. 1998;100:148-151.
150. Glassman AB, Hayes KJ. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2005;158:88-91.
151. Benharroch D, Meguerian-Bedoyan Z, Lamant L, et al. ALK-positive lymphoma: a single disease with a broad spectrum of morphology. Blood. 1998;91:2076-2084.
152. Foss HD, Anagnostopoulos I, Araujo I, et al. Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood. 1996;88:4005-4011.
153. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994;263:1281-1284.
154. Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623-5637.
155. Tan LH, Do E, Chong SM, et al. Detection of ALK gene rearrangements in formalin-fixed, paraffin-embedded tissue using a fluorescence in situ hybridization (FISH) probe: a search for optimum conditions of tissue archiving and preparation for FISH. Mol Diagn. 2003;7:27-33.
156. + anaplastic large cell lymphoma by interphase fluorescence in situ hybridization. Diagn Cytopathol. 2003;29:61-66.
157. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood. 1999;94:3509-3515.
158. Suzumiya J, Ohshima K, Kikuchi M, et al. Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections: a useful method for the diagnosis of lymphoblastic lymphoma. J Pathol. 1997;182:86-91.
159. Orazi A, Cattoretti G, John K, et al. Terminal deoxynucleotidyl transferase staining of malignant lymphomas in paraffin sections. Mod Pathol. 1994;7:582-586.
160. Orazi A, Cotton J, Cattoretti G, et al. Terminal deoxynucleotidyl transferase staining in acute leukemia and normal bone marrow in routinely processed paraffin sections. Am J Clin Pathol. 1994;102:640-645.
161. Drexler HG, Sperling C, Ludwig WD. Terminal deoxynucleotidyl transferase (TdT) expression in acute myeloid leukemia. Leukemia. 1993;7:1142-1150.
162. Muehleck SD, McKenna RW, Gale PF, et al. Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy. Am J Clin Pathol. 1983;79: 277-284.
163. Soslow RA, Bhargava V, Warnke RA. Mic2, TdT, bcl-2, and CD34 expression in paraffin-embedded high-grade lymphoma/ acute lymphoblastic leukemia distinguishes between distinct clinicopathologic entities. Hum Pathol. 1997;28:1158-1165.
164. Lin P, Jones D, Dorfman DM, et al. Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol. 2000;24:1480-1490.
165. Moricke A, Zimmermann M, Reiter A, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr. 2005;217:310-320.
166. Conde-Sterling DA, Aguilera NS, Nandedkar MA, et al. Immunoperoxidase detection of CD10 in precursor T-lymphoblastic lymphoma/leukemia: a clinicopathologic study of 24 cases. Arch Pathol Lab Med. 2000;124:704-708.
167. Szczepanski T, Beishuizen A, Pongers-Willemse MJ, et al. Cross-lineage T cell receptor gene rearrangements occur in more than ninety percent of childhood precursor-B acute lymphoblastic leukemias: alternative PCR targets for detection of minimal residual disease. Leukemia. 1999;13:196-205.
168. Pilozzi E, Muller-Hermelink HK, Falini B, et al. Gene rearrangements in T-cell lymphoblastic lymphoma. J Pathol. 1999;188:267-270.
169. Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002;197:341-347.
170. Razzouk BI, Srinivas S, Sample CE, et al. Epstein-Barr virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis. 1996;173:529-535.
171. Kelly GL, Milner AE, Tierney RJ, et al. Epstein-Barr virus nuclear antigen 2 (EBNA2) gene deletion is consistently linked with EBNA3A, -3B, and -3C expression in Burkitt's lymphoma cells and with increased resistance to apoptosis. J Virol. 2005;79:10709-10717.
172. Finke J, Fritzen R, Ternes P, et al. Expression of bcl-2 in Burkitt's lymphoma cell lines: induction by latent Epstein-Barr virus genes. Blood. 1992;80:459-469.
173. Frost M, Newell J, Lones MA, et al. Comparative immunohistochemical analysis of pediatric Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Clin Pathol. 2004;121:384-392.
174. Nakamura N, Nakamine H, Tamaru J, et al. The distinction between Burkitt lymphoma and diffuse large B-cell lymphoma with c-myc rearrangement. Mod Pathol. 2002;15:771-776.
175. zur Stadt U, Hoser G, Reiter A, et al. Application of long PCR to detect t(8;14)(q24;q32) translocations in childhood Burkitt's lymphoma and B-ALL. Ann Oncol. 1997;8(suppl 1):31-35.
176. Akasaka T, Ohno H, Mori T, et al. Long distance polymerase chain reaction for detection of chromosome translocations in B-cell lymphoma/leukemia. Leukemia. 1997;11(suppl 3):316-317.
177. Burmeister T, Schwartz S, Horst HA, et al. Molecular heterogeneity of sporadic adult Burkitt-type leukemia/lymphoma as revealed by PCR and cytogenetics: correlation with morphology, immunology and clinical features. Leukemia. 2005;19:1391-1398.
178. Siebert R, Matthiesen P, Harder S, et al. Application of interphase fluorescence in situ hybridization for the detection of the Burkitt translocation t(8;14)(q24;q32) in B-cell lymphomas. Blood. 1998;91:984-990.
179. Haralambieva E, Banham AH, Bastard C, et al. Detection by the fluorescence in situ hybridization technique of myc translocations in
180. Chang CC, Liu YC, Cleveland RP, et al. Expression of c-myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol. 2000;113:512-518.
181. Ladanyi M, Offit K, Jhanwar SC, et al. myc rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood. 1991;77:1057-1063.
182. Attygalle A, Al-Jehani R, Diss TC, et al. Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood. 2002;99:627-633.
183. Attygalle AD, Diss TC, Munson P, et al. CD10 expression in extranodal dissemination of angioimmunoblastic T-cell lymphoma. Am J Surg Pathol. 2004;28:54-61.
184. Yuan CM, Vergilio JA, Zhao XF, et al. CD10 and bcl6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ t cells by flow cytometry. Hum Pathol. 2005;36:784-791.
185. Borisch B, Caioni M, Hurwitz N, et al. Epstein-Barr virus subtype distribution in angioimmunoblastic lymphadenopathy. Int J Cancer. 1993;55:748-752.
186. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood. 1992;80:1804-1812.
187. Jones D, Jorgensen JL, Shahsafaei A, et al. Characteristic proliferations of reticular and dendritic cells in angioimmunoblastic lymphoma. Am J Surg Pathol. 1998;22:956-964.
188. Grogg KL, Attygalle AD, Macon WR, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol. 2006;19:1101-1107.
189. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol. 2006;30:490-494.
190. Kawano R, Ohshima K, Wakamatsu S, et al. Epstein-Barr virus genome level, T-cell clonality and the prognosis of angioimmunoblastic T-cell lymphoma. Haematologica. 2005;90:1192-1196.
191. Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant Hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol. 2003;27:1346-1356.
192. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96:1889-1899.
193. Burns BF, Colby TV, Dorfman RF. Differential diagnostic features of nodular L&H Hodgkin's disease, including progressive transformation of germinal centers. Am J Surg Pathol. 1984;8:253-261.
194. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood. 2003;102:3753-3758.
195. Ranjan P, Naresh KN. CD30 expression in L&H cells of Hodgkin's disease, nodular lymphocyte predominant type. Histopathology. 2003;42:406-407.
196. Tzankov A, Zimpfer A, Lugli A, et al. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin e1. J Pathol. 2003;199:201-207.
197. Stein H, Uchanska-Ziegler B, Gerdes J, et al. Hodgkin and Sternberg-Reed cells contain antigens specific to late cells of granulopoiesis. Int J Cancer. 1982;29:283-290.
198. Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
199. Kempf W, Levi E, Kamarashev J, et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J Cutan Pathol. 2002;29:295-300.
200. Fan G, Kotylo P, Neiman RS, et al. Comparison of fascin expression in anaplastic large cell lymphoma and Hodgkin disease. Am J Clin Pathol. 2003;119:199-204.
201. Kuppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. Int J Biochem Cell Biol. 2005;37:511-517.